Exagen Inc. (XGN)

Exagen Statistics

Total Valuation

Exagen has a market cap or net worth of $103.87 million. The enterprise value is $116.24 million.

Market Cap	103.87M
Enterprise Value	116.24M

Important Dates

The last earnings date was Monday, May 5, 2025, before market open.

Earnings Date	May 5, 2025
Ex-Dividend Date	n/a

Share Statistics

Exagen has 18.00 million shares outstanding. The number of shares has increased by 3.22% in one year.

Current Share Class	18.00M
Shares Outstanding	18.00M
Shares Change (YoY)	+3.22%
Shares Change (QoQ)	+0.70%
Owned by Insiders (%)	10.65%
Owned by Institutions (%)	30.32%
Float	9.50M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.87
Forward PS	1.56
PB Ratio	16.18
P/TBV Ratio	16.22
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	2.05
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.32, with a Debt / Equity ratio of 3.68.

Current Ratio	2.32
Quick Ratio	1.85
Debt / Equity	3.68
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-6.28

Financial Efficiency

Return on equity (ROE) is -117.50% and return on invested capital (ROIC) is -23.74%.

Return on Equity (ROE)	-117.50%
Return on Assets (ROA)	-19.21%
Return on Invested Capital (ROIC)	-23.74%
Return on Capital Employed (ROCE)	-53.23%
Revenue Per Employee	$263,833
Profits Per Employee	-$72,126
Employee Count	215
Asset Turnover	1.25
Inventory Turnover	6.74

Taxes

In the past 12 months, Exagen has paid $12,000 in taxes.

Income Tax	12,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +267.52% in the last 52 weeks. The beta is 1.51, so Exagen's price volatility has been higher than the market average.

Beta (5Y)	1.51
52-Week Price Change	+267.52%
50-Day Moving Average	4.52
200-Day Moving Average	3.71
Relative Strength Index (RSI)	54.02
Average Volume (20 Days)	308,903

Short Selling Information

The latest short interest is 90,485, so 0.50% of the outstanding shares have been sold short.

Short Interest	90,485
Short Previous Month	60,835
Short % of Shares Out	0.50%
Short % of Float	0.95%
Short Ratio (days to cover)	0.65

Income Statement

In the last 12 months, Exagen had revenue of $56.72 million and -$15.51 million in losses. Loss per share was -$0.84.

Revenue	56.72M
Gross Profit	33.64M
Operating Income	-14.00M
Pretax Income	-17.28M
Net Income	-15.51M
EBITDA	-12.29M
EBIT	-14.00M
Loss Per Share	-$0.84

Balance Sheet

The company has $11.19 million in cash and $23.56 million in debt, giving a net cash position of -$12.36 million or -$0.69 per share.

Cash & Cash Equivalents	11.19M
Total Debt	23.56M
Net Cash	-12.36M
Net Cash Per Share	-$0.69
Equity (Book Value)	6.40M
Book Value Per Share	0.36
Working Capital	18.51M

Cash Flow

Operating Cash Flow	-14.91M
Capital Expenditures	-542,000
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 59.30%, with operating and profit margins of -24.68% and -27.34%.

Gross Margin	59.30%
Operating Margin	-24.68%
Pretax Margin	-27.32%
Profit Margin	-27.34%
EBITDA Margin	-21.67%
EBIT Margin	-24.68%
FCF Margin	n/a

Dividends & Yields

Exagen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.22%
Shareholder Yield	-3.22%
Earnings Yield	-14.93%
FCF Yield	n/a

Analyst Forecast

The average price target for Exagen is $7.50, which is 29.98% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$7.50
Price Target Difference	29.98%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	13.87%
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Exagen has an Altman Z-Score of -8.64 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-8.64
Piotroski F-Score	4